FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964948224> ?p ?o ?g. }

• W1964948224 endingPage "769" @default.
• W1964948224 startingPage "763" @default.
• W1964948224 abstract "The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n=147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110 mg m−2, day 1 and 100 mg m−2, day 8) and cisplatin (80 mg m−2, day 8) (IC; n=74) or CDDP (80 mg m−2, day 1) (C; n=73) every 3 weeks. Patients treated with IC and C had a median survival of 7.8 and 8.8 months, respectively (P=0.933). The 1-year survival rate was 34.3% for IC-treated patients and 31.7% for C-treated patients. Cox's regression analysis revealed that response to treatment (hazard ratio (HR)=2.787; 95% confidence interval (CI): 1.1578–4.922) and performance status (HR=1.865; 95% CI: 1.199–2.872) was independent prognostic factors for survival. Overall response rate was 22.5% (95% CI: 12.8–32.2%) for IC-treated patients and 7.0% (95% CI: 1.15–13.6%) for C-treated patients (P=0.012); tumour growth control (partial remission (PR)+stable disease (SD)) was observed in 26 (38%) IC and 25 (36%) C patients (P=0.878). There was no difference in terms of quality of life between the two chemotherapy arms. The incidence of febrile neutropenia, grade 3 and 4 neutropenia and grade 3 and 4 diarrhoea was significantly higher in the IC- than the C-treated patients. Other toxicities were mild. There were no treatment-related deaths in either arm. The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate." @default.
• W1964948224 created "2016-06-24" @default.
• W1964948224 creator A5001577925 @default.
• W1964948224 creator A5002334565 @default.
• W1964948224 creator A5010312876 @default.
• W1964948224 creator A5014373065 @default.
• W1964948224 creator A5021248972 @default.
• W1964948224 creator A5026478600 @default.
• W1964948224 creator A5027952887 @default.
• W1964948224 creator A5035832029 @default.
• W1964948224 creator A5046050577 @default.
• W1964948224 creator A5049509860 @default.
• W1964948224 creator A5057590983 @default.
• W1964948224 creator A5072237244 @default.
• W1964948224 creator A5084377238 @default.
• W1964948224 date "2005-09-20" @default.
• W1964948224 modified "2023-10-18" @default.
• W1964948224 title "Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study" @default.
• W1964948224 cites W1839238860 @default.
• W1964948224 cites W1851083905 @default.
• W1964948224 cites W1853219928 @default.
• W1964948224 cites W1930536528 @default.
• W1964948224 cites W1969918779 @default.
• W1964948224 cites W1971928740 @default.
• W1964948224 cites W1974123654 @default.
• W1964948224 cites W2000712602 @default.
• W1964948224 cites W2011047883 @default.
• W1964948224 cites W2011797387 @default.
• W1964948224 cites W2017253303 @default.
• W1964948224 cites W2018913943 @default.
• W1964948224 cites W2019118371 @default.
• W1964948224 cites W2019929981 @default.
• W1964948224 cites W2028929367 @default.
• W1964948224 cites W2037154789 @default.
• W1964948224 cites W2057331147 @default.
• W1964948224 cites W2057363086 @default.
• W1964948224 cites W2062839616 @default.
• W1964948224 cites W2065498827 @default.
• W1964948224 cites W2071351256 @default.
• W1964948224 cites W2074190059 @default.
• W1964948224 cites W2083246890 @default.
• W1964948224 cites W2099072173 @default.
• W1964948224 cites W2116603453 @default.
• W1964948224 cites W2130652363 @default.
• W1964948224 cites W2134667653 @default.
• W1964948224 cites W2151784729 @default.
• W1964948224 cites W2153836018 @default.
• W1964948224 cites W2155236705 @default.
• W1964948224 cites W2161731922 @default.
• W1964948224 cites W2227314491 @default.
• W1964948224 cites W2326267475 @default.
• W1964948224 cites W2412863258 @default.
• W1964948224 cites W4232560465 @default.
• W1964948224 cites W4256121523 @default.
• W1964948224 cites W65154174 @default.
• W1964948224 cites W895291 @default.
• W1964948224 doi "https://doi.org/10.1038/sj.bjc.6602748" @default.
• W1964948224 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361638" @default.
• W1964948224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16175189" @default.
• W1964948224 hasPublicationYear "2005" @default.
• W1964948224 type Work @default.
• W1964948224 sameAs 1964948224 @default.
• W1964948224 citedByCount "43" @default.
• W1964948224 countsByYear W19649482242012 @default.
• W1964948224 countsByYear W19649482242013 @default.
• W1964948224 countsByYear W19649482242014 @default.
• W1964948224 countsByYear W19649482242015 @default.
• W1964948224 countsByYear W19649482242016 @default.
• W1964948224 countsByYear W19649482242017 @default.
• W1964948224 countsByYear W19649482242022 @default.
• W1964948224 crossrefType "journal-article" @default.
• W1964948224 hasAuthorship W1964948224A5001577925 @default.
• W1964948224 hasAuthorship W1964948224A5002334565 @default.
• W1964948224 hasAuthorship W1964948224A5010312876 @default.
• W1964948224 hasAuthorship W1964948224A5014373065 @default.
• W1964948224 hasAuthorship W1964948224A5021248972 @default.
• W1964948224 hasAuthorship W1964948224A5026478600 @default.
• W1964948224 hasAuthorship W1964948224A5027952887 @default.
• W1964948224 hasAuthorship W1964948224A5035832029 @default.
• W1964948224 hasAuthorship W1964948224A5046050577 @default.
• W1964948224 hasAuthorship W1964948224A5049509860 @default.
• W1964948224 hasAuthorship W1964948224A5057590983 @default.
• W1964948224 hasAuthorship W1964948224A5072237244 @default.
• W1964948224 hasAuthorship W1964948224A5084377238 @default.
• W1964948224 hasBestOaLocation W19649482241 @default.
• W1964948224 hasConcept C121608353 @default.
• W1964948224 hasConcept C126322002 @default.
• W1964948224 hasConcept C141071460 @default.
• W1964948224 hasConcept C143998085 @default.
• W1964948224 hasConcept C207103383 @default.
• W1964948224 hasConcept C2776256026 @default.
• W1964948224 hasConcept C2776694085 @default.
• W1964948224 hasConcept C2777063308 @default.
• W1964948224 hasConcept C2777511904 @default.
• W1964948224 hasConcept C2778239845 @default.
• W1964948224 hasConcept C2780258809 @default.
• W1964948224 hasConcept C2780259306 @default.
• W1964948224 hasConcept C2781413609 @default.

• next